Artículo de Revisión 19.- Boige V, Malka D, Bourredjem A, Dromain C, Baey C, Jacques N, et al. Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. Oncologist 2012; 17: 1063-72. 20.- Yau T, Chan P, Pang R, Ng K, Fan ST, Poon RT. Phase 1-2 trial of PTK787/ ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: implication for antiangiogenic approach to hepatocellular carcinoma. Cancer 2010; 116: 5022-9. 21.- Toh HC, Chen PJ, Carr BI, Knox JJ, Gill S, Ansell P, et al. Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer 2013; 119: 380-7. 22.- Zhu AX, Finn RS, Mulcahy M, Gurtler J, Sun W, Schwartz JD, et al. A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res 2013; 19: 6614-23. 23.- Bruix J, Tak WY, Gasbarrini A, Santoro A, Colombo M, Lim HY, et al. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer 2013; 49: 3412-9. 24.- O’Neil BH, Goff LW, Kauh JS, Strosberg JR, Bekaii-Saab TS, Lee RM, et al. Phase II study of the mitogen activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2011; 29: 2350-6. 25.- Lim HY, Heo J, Choi HJ, Lin CY, Yoon JH, Hsu C, et al. A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma. Clin Cancer Res 2014; 20: 5976-85. 26.- Alexia C, Fallot G, Lasfer M, Schweizer- Groyer G, Groyer A. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells 112 NUEVAS TERAPIAS EN CARCINOMA HEPATOCELULAR - M. Garrido S. et al. against drug induced apoptosis. Biochem Pharmacol 2004; 68: 1003-15. 27.- Hu TH, Huang CC, Lin PR, Chang HW, Ger LP, Lin YW, et al. Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer 2003; 97: 1929-40. 28.- Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008; 135: 1972-83. 29.- Zhu AX, Stuart K, Blaszkowsky LS, Muzikansky A, Reitberg DP, Clark JW, et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 2007; 110: 581-9. 30.- Thomas MB, Chadha R, Glover K, Wang X, Morris J, Brown T, et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007; 110: 1059-67. 31.- Philip PA, Mahoney MR, Holen KD, Northfelt DW, Pitot HC, Picus J, et al. Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer. Cancer 2012; 118: 2424-30. 32.- Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, et al. A multi-institutional phase II study of the efficacy and tolerability oflapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res 2009; 15: 5895-901. 33.- Abou-Alfa GK, Capanu M, O´Reille EM, Ma J, Chou JF, Gansukh B, et al. Phase II Study of Cixutumumab (IMC-A12, NSC742460; C) in Advanced Hepatocellular Carcinoma. J Hepatol 2014; 60: 319-24. 34.- Decaens T, Luciani A, Itti E, Hulin A, Roudot-Thoraval F, Laurent A, et al. Phase II study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma. Dig Liver Dis 2012; 44: 610-6. 35.- Zhu AX, Abrams TA, Miksad R, Blaszkowsky LS, Meyerhardt JA, Zheng H, et al. Phase ½ study of everolimus in advanced hepatocellular carcinoma. Cancer 2011; 117: 5094-02. 36.- Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008; 7: 504-16. 37.- Wu F, Wu L, Zheng S, Ding W, Teng L, Wang Z, et al. The clinical value of hepatocyte growth factor and its receptor c-met for liver cancer patients with hepatectomy. Dig Liver Dis 2006; 38: 490-7. 38.- Boix L, Rosa JL, Ventura F, Castells A, Bruix J, Rodes J, et al. c-met mRNA over expression in human hepatocellular carcinoma. Hepatology 1994; 19: 88-91. 39.- Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 2013; 14: 55-63. 40.- Verslype C, Cohn AL, Kelley R, Yang TS, Su WC, Ramies D, et al. Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT). J Clin Oncol 2012; 30: Suppl 4007. 41.- Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y, Villanueva A, et al. Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol 2012; 6: 1343-50. 42.- Venturelli S, Armeanu S, Pathil A, Hsieh CJ, Weiss TS, Vonthein R, et al. Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. Cancer 2007; 109: 2132-41. 43.- Li M, Zhao H, Zhang X, Wood LD, Anders RA, Choti MA, et al. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet 2011; 43: 828-9. 44.- Nagai T, Arao T, Furuta K, Sakai K, Kudo K, Kaneda H, et al. Sorafenib inhibits the hepatocyte growth factormediated epithelial mesenchymal transition in hepatocellular carcinoma. Mol Cancer Ther 2011; 10: 169-77. 45.- El Idrissi M, Hervieu V, Merle P, Mortreux F, Wattel E. Cause-specific telomere factors deregulation in hepatocellular carcinoma. J Exp Clin Cancer Res 2013; 32: 64. 46.- Zhang B, Chen J, Cheng AS, Ko BC. Depletion of sirtuin 1 (SIRT1) leads to epigenetic modifications of telomerase Gastroenterol. latinoam 2016; Vol 27, Nº 2: 106-113
gastro 2 2016
To see the actual publication please follow the link above